Neurology News and Research

Latest Neurology News and Research

GIND scientists identify drug treatments that can normalize neuron development in AD

Scientists at the Gladstone Institute of Neurological Disease (GIND) have discovered that two main causes of AD amyloid-beta (Aβ) peptides and apolipoprotein E4 (apoE4) impair the growth of new neurons born in adult brains. What is more, they have identified drug treatments that can normalize the development of these cells even in the presence of Aβ or apoE4. The findings are described in two separate papers published in the current issue of Cell Stem Cell.

4 Dec 2009

New research trial to study the impact of exercise on Parkinson's patients

Officials at the new Muhammad Ali Parkinson Center at Barrow Neurological Institute announced today the center's participation in a novel Parkinson's study aimed at determining the physical and neurological impact of simple exercise on Parkinson's patients.

4 Dec 2009

Study shows younger, female and Hispanic stroke survivors are less likely to take antithrombotic medications

People who have had an ischemic stroke are at higher lifetime risk for another stroke, but several types of medication can reduce that risk. One of the simplest regimens involves antithrombotic medications, otherwise known as blood thinners, of which the most common is aspirin.

3 Dec 2009

Endo Pharmaceuticals receives FDA complete response letter for AVEED NDA

Endo Pharmaceuticals today announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for its extended-duration testosterone undecanoate injection, AVEED(TM), for men diagnosed with low testosterone.

3 Dec 2009

AclarusDx Alzheimer’s test now available as RUO product

ExonHit Therapeutics is pleased to announce that AclarusDx™ Alzheimer’s test (formerly known as EHT Dx21), its blood-based test for the detection of Alzheimer’s disease (AD), is now available as a Research Use Only (RUO) product for pharmaceutical companies and leading academic centers conducting clinical trials in Alzheimer’s disease.

3 Dec 2009

Repeated use of ecstasy drug increases the risk of developing sleep apnea

Repeated use of the drug popularly known as "ecstasy" significantly raises the risk of developing sleep apnea in otherwise healthy young adults with no other known risk factors for the sleep disturbance, a new study by Johns Hopkins scientists suggests.

2 Dec 2009

Sepracor to present clinical study data of STEDESA at the 2009 AES meeting

Sepracor Inc. today announced that clinical study data for STEDESA™ (eslicarbazepine acetate) will be presented at the 2009 annual meeting of the American Epilepsy Society (AES) in Boston. Seven posters describing new safety analyses will be presented at the Hynes Convention Center during the formal poster session on Saturday, December 5, 2009 between 1:00 pm and 8:00 pm EST.

2 Dec 2009

A leader in the fight against brain diseases and in drug discovery joins UF

A leader in the fight against brain diseases and in drug discovery to help Alzheimer's patients has joined the University of Florida College of Medicine, interim dean Michael Good, M.D., announced.

2 Dec 2009

Ecotones Duet Sleep Sound Machine recommended as part of a healthy sleep plan

Last month on a prominent nationally syndicated radio show, Dr. Rafael Pelayo, Associate Professor at the Stanford Sleep Disorders Clinic at Stanford University School of Medicine, recommended the Ecotones Duet Sleep Sound Machine as part of a healthy sleep plan for people trying to achieve a better night's sleep with minimal use of drugs.

2 Dec 2009

Roche announces results of phase III taspoglutide study in diabetes patients

Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of the second and third of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s research and developed by Roche.

2 Dec 2009

Study examines role of low-oxygen exposure in heart failure patients

Distance runners who live at high altitudes with low oxygen levels are known to improve their performance during races in areas that are at sea level. Can heart failure patients, who suffer from fatigue, improve their exercise performance by staying in a tent-like, high-altitude simulator?

1 Dec 2009

Article on TYSABRI for treating patients with multiple sclerosis published

Best-practice recommendations for the selection and management of patients with multiple sclerosis (MS) who may benefit from, or are receiving treatment with TYSABRI- (natalizumab) were published today in a supplement to the medical journal Multiple Sclerosis.

1 Dec 2009

Americans living in the Southern region may have elevated risk of dying from stroke

The "stroke belt" has a tight hold. People born in the Southern stroke belt have a higher risk of dying from stroke as adults, even if they later move away, compared to people who were born in other parts of the country.

1 Dec 2009

Bayer Healthcare Pharmaceuticals commences enrollment in florbetaben Phase III clinical trials

Today at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Bayer HealthCare Pharmaceuticals Inc. announced the enrollment of the first patient in an international Phase III clinical trial to evaluate the efficacy and safety of florbetaben (BAY 94-9172) PET imaging in the detection of beta-Amyloid plaques in the brain, which are a pathological hallmark of Alzheimer's disease.

30 Nov 2009

ALS research collaboration receives philanthropic funding

Three prominent philanthropic organizations – The Angel Fund, The ALS Therapy Alliance and Project ALS -- dedicated to finding a treatment for amyotrophic lateral sclerosis (ALS) have financed a new collaboration between one of the world’s leading ALS researchers and RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi).

30 Nov 2009

Toshiba introduces new CT system for pediatric imaging

With smaller vessels, lower bone density and less body fat, pediatric patients have different imaging needs than adults. Pediatric patients frequently have difficulty holding their breath or staying still during a scan, creating the need for CT technology tailored for their needs.

30 Nov 2009

Siemens Healthcare to showcase latest medical imaging technologies at RSNA 2009

At the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), "Images, my way" will resonate throughout the Siemens Healthcare booth (#825) from November 29 to December 3 at McCormick Place (Booth #825, East Building/Lakeside Center, Hall D) in Chicago.

30 Nov 2009

Siemens Healthcare introduces syngo.via at RSNA annual meeting

Get ready for advanced visualization to become common practice in the clinical routine when Siemens introduces syngo.via at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from November 29 to December 3 at McCormick Place (Booth #825, East Building/Lakeside Center, Hall D) in Chicago.

30 Nov 2009

New approach for repairing damaged nerve fibers in spinal cord injuries using nano-spheres discovered

Researchers at Purdue University have discovered a new approach for repairing damaged nerve fibers in spinal cord injuries using nano-spheres that could be injected into the blood shortly after an accident.

27 Nov 2009